Currently, out of the existing stock ratings of Ami Fadia - 185 which are a Buy (86.05%), 25 which are a Hold (11.63%), 5 which are a Sell (2.33%)

Ami Fadia

Work Performance Price Targets & Ratings Chart

Analyst Ami Fadia works at NEEDHAM and is covering the Healthcare sector with 431 price targets and ratings displayed on 30 stocks. Previously, Ami Fadia worked at LEERINK.

Ami Fadia's average stock forecast success ratio is 43.59% with an average time for price targets to be met of 116.1 days.

Most recent stock forecast was given on AVDL, Avadel Pharmaceuticals plc at 25-Sep-2023.

Wall Street Analyst Ami Fadia

Analyst best performing recommendations are on MNK.
The best stock recommendation documented was for SGEN (SEATTLE GENETICS) at 2/23/2023. The price target of $178 was fulfilled within 4 days with a profit of $15.81 (9.75%) receiving and performance score of 24.37.

Average potential price target upside

of $54.76 (24.55%) on BIIB (BIOGEN).
of $37.98 (29.26%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $29.7 (21.21%) on SGEN (SEATTLE GENETICS).

AMRN Amarinplc ARDX Ardelyx AVDL Avadel Pharmaceuticals plc BIIB Biogen HRMY Harmony Biosciences Holdings HRTX Heron Therapeutics JAZZ Jazz Pharmaceuticals plc MYOV Myovant Sciences Ltd OBSV ObsEva SA SAGE Sage Therapeutics BCYC Bicycle Therapeutics plc ITCI IntraCellular Therapies MNK MRUS Merus N.V NBIX Neurocrine Biosciences TEVA Teva Pharmaceutical Industries ACAD ACADIA Pharmaceuticals AMRX Amneal Pharmaceuticals MYL PCRX Pacira BioSciences SGEN Seattle Genetics VTRS DAWN ASRT BPMC Blueprint Medicines COGT ENDP Endo International plc PRGO Perrigo Company plc RVMD THRX

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Paul Choi (GOLDMAN)